Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples